IVD Clinical Trial Monitoring Should Be Higher Priority For Manufacturers
This article was originally published in The Gray Sheet
Executive SummaryDevelopers of in vitro diagnostics should make the monitoring of investigators a key part of their clinical trial protocols, speakers at the Oct. 26-27 Association Medical Diagnostics Manufacturers' annual meeting in Rockville, Maryland cautioned.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.